A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

Recruiting now · Phase 1

Conditions studied: Moderate Hepatic Impairment

In brief

The purpose of this study is to measure the pharmacokinetics (PK), safety, and tolerability of capivasertib in participants with moderate hepatic impairment and participants with normal hepatic function (as control).

Key facts

Study ID

NCT07343960

Run by

AstraZeneca

People needed

20

Starts

2026-01-06

Expected to finish

2026-11-11

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

Where it is running

• Research Site — Rialto, California, United States (enrolling)
• Research Site — San Antonio, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.